174 related articles for article (PubMed ID: 36959936)
1. A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters.
Margolin E; Schäfer G; Allen JD; Gers S; Woodward J; Sutherland AD; Blumenthal M; Meyers A; Shaw ML; Preiser W; Strasser R; Crispin M; Williamson AL; Rybicki EP; Chapman R
Front Plant Sci; 2023; 14():1146234. PubMed ID: 36959936
[TBL] [Abstract][Full Text] [Related]
2. Augmenting glycosylation-directed folding pathways enhances the fidelity of HIV Env immunogen production in plants.
Margolin E; Allen JD; Verbeek M; Chapman R; Meyers A; van Diepen M; Ximba P; Motlou T; Moore PL; Woodward J; Strasser R; Crispin M; Williamson AL; Rybicki EP
Biotechnol Bioeng; 2022 Oct; 119(10):2919-2937. PubMed ID: 35781691
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein.
Zhang S; Go EP; Ding H; Anang S; Kappes JC; Desaire H; Sodroski JG
J Virol; 2022 Feb; 96(3):e0162621. PubMed ID: 34817202
[TBL] [Abstract][Full Text] [Related]
4. A Roadmap for the Molecular Farming of Viral Glycoprotein Vaccines: Engineering Glycosylation and Glycosylation-Directed Folding.
Margolin E; Crispin M; Meyers A; Chapman R; Rybicki EP
Front Plant Sci; 2020; 11():609207. PubMed ID: 33343609
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
6. Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2.
Braun MR; Martinez CI; Dora EG; Showalter LJ; Mercedes AR; Tucker SN
Front Immunol; 2023; 14():1086035. PubMed ID: 36911687
[TBL] [Abstract][Full Text] [Related]
7. Site-Specific Glycosylation of Recombinant Viral Glycoproteins Produced in
Margolin E; Allen JD; Verbeek M; van Diepen M; Ximba P; Chapman R; Meyers A; Williamson AL; Crispin M; Rybicki E
Front Plant Sci; 2021; 12():709344. PubMed ID: 34367227
[TBL] [Abstract][Full Text] [Related]
8. Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters.
Liu X; Park HS; Matsuoka Y; Santos C; Yang L; Luongo C; Moore IN; Johnson RF; Garza NL; Zhang P; Lusso P; Best SM; Buchholz UJ; Le Nouën C
bioRxiv; 2022 Dec; ():. PubMed ID: 36561185
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the
Balieu J; Jung JW; Chan P; Lomonossoff GP; Lerouge P; Bardor M
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014368
[TBL] [Abstract][Full Text] [Related]
10. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
11. CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge.
Lien CE; Lin YJ; Chen C; Lian WC; Kuo TY; Campbell JD; Traquina P; Lin MY; Liu LT; Chuang YS; Ko HY; Liao CC; Chen YH; Jan JT; Ma HH; Sun CP; Lin YS; Wu PY; Wang YC; Tao MH; Lin YL
Sci Rep; 2021 Apr; 11(1):8761. PubMed ID: 33888840
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 spike trimer vaccine expressed in Nicotiana benthamiana adjuvanted with Alum elicits protective immune responses in mice.
Song SJ; Kim H; Jang EY; Jeon H; Diao HP; Khan MRI; Lee MS; Lee YJ; Nam JH; Kim SR; Kim YJ; Sohn EJ; Hwang I; Choi JH
Plant Biotechnol J; 2022 Dec; 20(12):2298-2312. PubMed ID: 36062974
[TBL] [Abstract][Full Text] [Related]
13. Analysis of glycosylation and disulfide bonding of wild-type SARS-CoV-2 spike glycoprotein.
Zhang S; Go EP; Ding H; Anang S; Kappes JC; Desaire H; Sodroski J
bioRxiv; 2021 Apr; ():. PubMed ID: 33821278
[TBL] [Abstract][Full Text] [Related]
14. The "humanized" N-glycosylation pathway in CRISPR/Cas9-edited Nicotiana benthamiana significantly enhances the immunogenicity of a S/preS1 Hepatitis B Virus antigen and the virus-neutralizing antibody response in vaccinated mice.
Pantazica AM; van Eerde A; Dobrica MO; Caras I; Ionescu I; Costache A; Tucureanu C; Steen H; Lazar C; Heldal I; Haugslien S; Onu A; Stavaru C; Branza-Nichita N; Liu Clarke J
Plant Biotechnol J; 2023 Jun; 21(6):1176-1190. PubMed ID: 36779605
[TBL] [Abstract][Full Text] [Related]
15. An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge.
Honda-Okubo Y; Li L; André G; Leong KH; Howerth EW; Bebin-Blackwell AG; Ross TM; Petrovsky N
Vaccine; 2023 Jul; 41(32):4710-4718. PubMed ID: 37355452
[TBL] [Abstract][Full Text] [Related]
16. Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters.
Abdelnabi R; Pérez P; Astorgano D; Albericio G; Kerstens W; Thibaut HJ; Coelmont L; Weynand B; Labiod N; Delgado R; Montenegro D; Puentes E; Rodríguez E; Neyts J; Dallmeier K; Esteban M; García-Arriaza J
Front Immunol; 2023; 14():1163159. PubMed ID: 37920464
[TBL] [Abstract][Full Text] [Related]
17. A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants.
Jiang L; Driedonks TAP; Jong WSP; Dhakal S; Bart van den Berg van Saparoea H; Sitaras I; Zhou R; Caputo C; Littlefield K; Lowman M; Chen M; Lima G; Gololobova O; Smith B; Mahairaki V; Riley Richardson M; Mulka KR; Lane AP; Klein SL; Pekosz A; Brayton C; Mankowski JL; Luirink J; Villano JS; Witwer KW
J Extracell Vesicles; 2022 Mar; 11(3):e12192. PubMed ID: 35289114
[TBL] [Abstract][Full Text] [Related]
18. Site specific N- and O-glycosylation mapping of the spike proteins of SARS-CoV-2 variants of concern.
Shajahan A; Pepi LE; Kumar B; Murray NB; Azadi P
Sci Rep; 2023 Jun; 13(1):10053. PubMed ID: 37344512
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits.
O'Kennedy MM; Abolnik C; Smith T; Motlou T; Goosen K; Sepotokele KM; Roth R; du Preez I; Truyts A; Stark HC; Magwaza M; Mahanjana O; Verschoor JA; Moore PL; Lemmer Y
Vaccine; 2023 Mar; 41(13):2261-2269. PubMed ID: 36868876
[TBL] [Abstract][Full Text] [Related]
20. A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models.
Maruggi G; Mallett CP; Westerbeck JW; Chen T; Lofano G; Friedrich K; Qu L; Sun JT; McAuliffe J; Kanitkar A; Arrildt KT; Wang KF; McBee I; McCoy D; Terry R; Rowles A; Abrahim MA; Ringenberg MA; Gains MJ; Spickler C; Xie X; Zou J; Shi PY; Dutt T; Henao-Tamayo M; Ragan I; Bowen RA; Johnson R; Nuti S; Luisi K; Ulmer JB; Steff AM; Jalah R; Bertholet S; Stokes AH; Yu D
Mol Ther; 2022 May; 30(5):1897-1912. PubMed ID: 34990810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
